Johnson Matthey, Domainex Collaborate
News Apr 19, 2016
Johnson Matthey and Domainex Ltd. have announced a collaboration to provide integrated small molecule pharmaceutical discovery and development services. The focus will be on providing academic institutes, biotechnology and pharmaceutical companies across the UK and beyond with effective, simplified, rapid and reduced risk target-to-lead identification, optimisation, safety/toxicology, pre-clinical and clinical API supply services.
Domainex is a leading provider of small molecule drug discovery services that complement the pre-clinical to commercial range of services provided by Johnson Matthey Fine Chemicals’ Custom Pharma Solutions offering in Europe. Through an integrated offering co-located in the Cambridge region, customers will be able to access Domainex’s target-to-lead identification and optimisation capabilities, and will then be able to transfer their projects directly to Johnson Matthey, utilising its Pharmorphix solid state services for effective salt form and polymorph identification through to process development, scale-up and non-GMP toxicology manufacture. With all activities co-located in the Cambridge area, discovery and development time and risk can be greatly minimised.
“Johnson Matthey and Domainex have together recognised there is customer demand for simplified and effective drug discovery and development services.
With our combined expertise and facilities based in Cambridge, UK, we are now able to offer customers significant value through this joint service offering,” said Antoine Bordet, European Managing Director at Johnson Matthey Fine Chemicals.
“The transition from drug discovery and candidate nomination into polymorph screening, pre-clinical toxicology and Phase I clinical development is a critical phase in the drug development process,” added Tom Mander, COO of Domainex. “We’re bringing together the necessary complementary people, skills and facilities with Johnson Matthey so that together we can offer an integrated and simplified solution spanning pharmaceutical discovery through to clinical development.”
Compound Offers Pain-relief of Opioids Without Addictive PropertiesNews
Researchers have engineered a new compound that animal tests suggest could offer the pain-relieving properties of opioids such as morphine and oxycodone without the risk of addiction.READ MORE
Compound Selectively Kills Liver Cancer Stem CellsNews
Acyclic retinoid, an artificial compound derived from vitamin A, has been found to prevent the recurrence of hepatocellular carcinoma (HCC), the most common form of liver cancer.READ MORE
170 Potential Lung Cancer Drug Targets Identified Using Unique Cellular LibraryNews
After testing more than 200,000 chemical compounds, UT Southwestern’s Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.READ MORE